Cara Therapeutics, Inc.
NASDAQ:CARA
Overview | Financials
Company Name | Cara Therapeutics, Inc. |
Symbol | CARA |
Currency | USD |
Price | 0.297 |
Market Cap | 16,289,440 |
Dividend Yield | 0% |
52-week-range | 0.24 - 1.4 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Christopher A. Posner |
Website | https://www.caratherapeutics.com |
An error occurred while fetching data.
About Cara Therapeutics, Inc.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD